DNA X, Inc. cash flow to debt ratio of -464.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

DNA X, Inc.'s free cash flow has decreased 170.41% from $-8.70M last year to $-23.53M, signaling decreasing performance

DNA X, Inc.'s debt to equity ratio is -12.92, signaling that the company spent its equity and risk bankruptcy.

DNA X, Inc. has insufficient data to evaluate this check.

DNA X, Inc. has negative EBITDA, making leverage ratio unreliable

DNA X, Inc.'s interest coverage ratio is -6.34, which means that the company struggles to meet interest obligations, signaling financial risk.

DNA X, Inc.'s profit margin has increased (-253.09%) in the last year from -57.72% to 88.36%, signaling increasing performance

DNA X, Inc.'s short-term liabilities of $48.03M exceed its short-term assets of $28.91M, signaling financial risk

DNA X, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

DNA X, Inc.'s return on equity of 668.17%, is higher than 15.00%, indicating good performance

DNA X, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

DNA X, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

DNA X, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

DNA X, Inc. has negative free cash flow, indicating cash burn

DNA X, Inc.'s yearly earnings has increased -38.61% since last year from $-33.65M to $-20.66M, signaling increasing performance

DNA X, Inc.'s yearly revenue has decreased 100.00% since last year from $58.30M to $0.00, signaling decreasing performance

ROIC -101.13% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

DNA X, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

DNA X, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

DNA X, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

DNA X, Inc. has insufficient data to evaluate this check.

DNA X, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

DNA X, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

DNA X, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

DNA X, Inc. has insufficient data to evaluate this check.

DNA X, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

DNA X, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

DNA X, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue